Companies · Biotechnology

MaraBio Systems Inc.

SALT LAKE CITY · Biotechnology

Diligence memoA one-page analyst read on MaraBio Systems Inc. — recommendation, valuation, rhythm, risks.
$19.1M
Total raised · real
1
Rounds
Latest step-up
Top 34%
Sector rank · raised
Series B
Latest stage · inferred · Mon Sep 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

MaraBio Systems Inc. looks fair against its niche peers and is quiet on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Fair
  • Modeled value is 0.74× the median modeled value of Series B Biotechnology companies in 2022–2024 (197 peers) — value vs value, same stage and era.
  • Within the normal band (74% of peer median) for its niche.
Quiet
  • Last raise 21 mo ago; this sector typically re-raises about every 14 months.
  • Slightly overdue versus sector cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

MaraBio Systems Inc. is one of 4293 Biotechnology companies tracked from SALT LAKE CITY. By capital raised it ranks mid-pack (ahead of 67% of sector peers), and mid-pack by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
25
Investors (latest)
2024-09-16
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$50M$100M$150M$200MSeries B · 2024-09-16 Raised $19M (real) Modeled valuation $124M (est)$19M$124MSeries B2024

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series B$19.1M · 2024

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed, Series A — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 25%.

Modeled valuation trajectory
$124.2M
Base estimate est.
$38.1M
Conservative case
$213.6M
Upside case
$105.9M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Ba $15M–$40M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Not enough modeled valuation points to chart a trajectory.

Model inputs · modeled:benchmark-stage-stepup-v1
18%
Dilution assumption
Implied ownership sold in the financing.
54%
Survival probability
36% low · 66% high
1.54×/yr
Annual markup
1.86×/yr upside case
1.8 yr
Elapsed time used
1.8 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
Avg between rounds
Capital velocity
1.8 yr
On record since
2024
First round
1
Rounds on file
How it compares to the market

Benchmarked against 4293 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 2.6× above median
This company$19.1M
Sector median$7.2M
Latest round — vs other Series B rounds in sector (real $, this stage) 1.1× above median
This company$19.1M
Sector median$17.5M
Modeled value — vs sector median (estimate, all stages) 1.9× above median
This company$124.2M
Sector median$64.2M

Raised more than 67% of sector peers (real $). Modeled value above 63% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series B) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #127 of 197.

This companyCohort peer
$100.0M$1.0B$10.0M$100.0M$1.0BCapital raised (log)Mt McKinley Medical Holding Corp USA · Series B Raised $40.0M · modeled $738.4M (est)YAP Therapeutics Inc · Series B Raised $30.1M · modeled $618.3M (est)Pinteon Therapeutics, Inc. · Series B Raised $39.2M · modeled $603.8M (est)OncXerna Therapeutics, Ltd. · Series B Raised $30.0M · modeled $591.4M (est)EpiBiologics, Inc. · Series B Raised $30.0M · modeled $570.2M (est)GIOGI Ltd · Series B Raised $27.3M · modeled $554.5M (est)SonoThera, Inc. · Series B Raised $30.4M · modeled $550.9M (est)Perceive Biotherapeutics, Inc. · Series B Raised $40.0M · modeled $544.6M (est)GIOCAN Ltd · Series B Raised $24.5M · modeled $498.6M (est)GIODIA Ltd · Series B Raised $24.5M · modeled $498.6M (est)GIOHEALTH Ltd · Series B Raised $24.5M · modeled $498.6M (est)Cerapedics Inc · Series B Raised $99.1M · modeled $492.3M (est)MaraBio Systems Inc. (this company) Raised $19.1M · modeled $124.2M (est)MaraBio Systems Inc.
CompanyStageRaised · realValue · estvs peer med.
Mt McKinley Medical Holding Corp USASeries B$40.0M$738.4M4.41×
YAP Therapeutics IncSeries B$30.1M$618.3M3.69×
Pinteon Therapeutics, Inc.Series B$39.2M$603.8M3.60×
OncXerna Therapeutics, Ltd.Series B$30.0M$591.4M3.53×
EpiBiologics, Inc.Series B$30.0M$570.2M3.40×
GIOGI LtdSeries B$27.3M$554.5M3.31×
SonoThera, Inc.Series B$30.4M$550.9M3.29×
Perceive Biotherapeutics, Inc.Series B$40.0M$544.6M3.25×
GIOCAN LtdSeries B$24.5M$498.6M2.97×
GIODIA LtdSeries B$24.5M$498.6M2.97×
GIOHEALTH LtdSeries B$24.5M$498.6M2.97×
Cerapedics IncSeries B$99.1M$492.3M2.94×
MaraBio Systems Inc. this companySeries B$19.1M$124.2M0.74×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series B$19.1M2024-09-16$105.9M$124.2M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series B$19.1M2024-09-16
    • First recorded raise — entered as Series B.
    • 25 investors on this round.
Intelligence
Modeled next raise
$30.5M
Modeled next size est.range $19.8M$48.8M
Last step-up
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
MICHAEL KAUFMAN6 other2024-09
Craig Nemiroff3 other2024-09
Gail Page3 other2024-09
Michael Paul2 other2024-09
Vincent Forlenza2024-09
Registry & provenance

MaraBio Systems Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
2039520
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Trailhead Biosystems Inc.BiotechnologySeries B$41.7M$75.7Mnetwork2 shared operators · same sector · same stage
Noveome Biotherapeutics, Inc.BiotechnologySeries B$54.8M$382.2Mnetwork2 shared operators · same sector · same stage
Brainsway Ltd.BiotechnologySeries B$20.0M$128.4Msame sector · same stage
Tempo Therapeutics, Inc.BiotechnologySeries B$20.2M$134.4Msame sector · same stage
Immunis, Inc.BiotechnologySeries B$20.4M$147.9Msame sector · same stage
Affini-T Therapeutics, Inc.BiotechnologySeries B$17.6M$121.3Msame sector · same stage
Xylocor Therapeutics, Inc.BiotechnologySeries B$21.4M$126.0Msame sector · same stage
Pep2Tango Therapeutics, Inc.BiotechnologySeries B$16.7M$108.3Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
BioROSA Technologies IncBiotechnologySeed$8.9M88%
Arvinas, Inc.BiotechnologySeries C$1.3B87%
StemBioSys Inc.BiotechnologySeries A$43.9M87%
Orionis Biosciences LLCBiotechnologySeries B$782.6M87%
Caladrius Biosciences, Inc.BiotechnologySeries B$777.5M87%
biOasis Technologies Inc.BiotechnologySeed$74.9M87%
RenBio, Inc.BiotechnologySeries A$25.7M87%
Mosaic Biosciences, Inc.BiotechnologySeries A$176.4M87%
Frequently asked
How much funding has MaraBio Systems Inc. raised?
MaraBio Systems Inc. has raised approximately $19.1M in disclosed capital across 1 recorded financing round, aggregated from public filings.
What is MaraBio Systems Inc.'s estimated valuation?
Provath's modeled valuation for MaraBio Systems Inc. is approximately $124.2M (modeled range $38.1M–$213.6M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is MaraBio Systems Inc. at?
MaraBio Systems Inc.'s latest modeled financing stage is Series B. Its most recent recorded round closed around Mon Sep 16.
What does MaraBio Systems Inc. do and where is it based?
MaraBio Systems Inc. operates in the Biotechnology sector, based in SALT LAKE CITY.
Explore related

See where MaraBio Systems Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at MaraBio Systems Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.